Savić M, Djukanović Lj, Sinkjić M, Blagojević R, Ostrić V
Department of Nephrology, Clinical Centre of Serbia, Belgrade.
Srp Arh Celok Lek. 1996 Jan-Feb;124(1-2):11-3.
Chronic rejection of kidney transplant is a chronic and progressive decline of kidney transplant function related to certain morphologic changes, such as obliterate vasculopathy, interstitial fibrosis, tubular atrophy, and transplant glomerulopathy [1]. The purpose of this study was to investigate the involvement of chronic transplant glomerulopathy in the progression of chronic renal failure.
METHOD, PATIENTS: Of 16 transplant patients with histologic diagnosis of chronic kidney transplant rejection in biopsy specimens, 8 patients had chronic transplant glomerulopathy (ChR-1), and in the other 8 patients glomeruli were relatively preserved (ChR-2). Transplant biopsies were performed between the seventh and the 15th month in ChR-1, and between the ninth and the 34th month in ChR-2 group. Morphologic vasculopathy cv2 changes, tubular atrophy ct1 and ct2 in the half of each group, and interstitial fibrosis ci2, were graded according to the BANFF criteria [2]. During the follow up the patients received similar doses of prednisone, as well as of azathioprine and cyclosporine A.
The expression of MHC I antigen, MHC II antigens, CD3, CD25, CD54 (ICAM-1) was analyzed by indirect immunoperoxidase technique of staining on the frozen sections, (DAKOPATTS). The immunoreactivity score was 0 to 3.
The renal function was expressed as reciprocal serum creatinine values (1/mumol/L) reflecting the mean monthly levels, over the period between the third and the 22nd month following the transplantation. In each patient a decline in kidney functioning was determined in two ways: 1. by the slope of the curve representing the function of regression of the reciprocal serum creatinine over time, started from the third month after the transplantation, 2. by the rate of regression (percent) of the reciprocal serum creatinine values at the sixth, the ninth, the 18th and the 22nd month, compared to the attained serum creatinine level at the third posttransplantation month.
Glomeruli with present chronic transplant glomerulopathy (patients of the ChR-1 group) had moderate expression of MHC I antigen [1-2], week expression of ICAM-1 (CD54), whereas DR antigens were almost absent. In cortical tubuli the expression of MHC I antigen was very low. The relatively preserved glomeruli in patients without chronic transplant glomerulopathy (ChR-2 group) showed high expression of MHC I antigen [2], moderate expression of ICAM-1, and low (up to 1) DR expression. The CD25 molecules were not detected in any analyzed glomeruli (62 in total), except a positive cellular crescent formation, seen in 3 patients with chronic transplant glomerulopathy. The regression slopes of reciprocal serum creatinine values according to months, over the third and the 22nd month were similar in both groups of patients, and the speculating mean graft survival time was 44 months, in both groups. However, 4 of 8 patients of the ChR-1 group, and only 1 of 8 patients of the ChR-2 group returned to the haemodialyses because of the graft functioning loss. Besides, the mean percentual rate of the decline in renal functioning, as the rate of decrease of serum reciprocal creatinine values in the chosen growing periods in time after the third month were higher in group ChR-1 with present chronic transplant glomerulopathy in biopsy specimens. The difference was of statistical significance at the end of the 18th month, t = 4.10, p less than 0.01. In this period proteinuria exceeding 3 grams a day was discovered in 6 patients of ChR-1 group, and in 4 patients in ChR-2 group. Our results suggest that the early appearance of chronic transplant glomerulopathy induces a slightly higher loss of function of the kidney transplant with chronic rejection, despite of the absence of the immune activation in the glomeruli with the present chronic transplant glomerulopathy. (ABSTRACT TRUNCATED)
肾移植慢性排斥反应是与某些形态学改变相关的肾移植功能的慢性进行性下降,如闭塞性血管病、间质纤维化、肾小管萎缩和移植性肾小球病[1]。本研究的目的是调查慢性移植性肾小球病在慢性肾衰竭进展中的作用。
方法、患者:在16例活检标本组织学诊断为慢性肾移植排斥反应的移植患者中,8例患有慢性移植性肾小球病(ChR-1),另外8例患者的肾小球相对保存完好(ChR-2)。ChR-1组在第7至15个月进行移植肾活检,ChR-2组在第9至34个月进行移植肾活检。根据班夫标准[2]对每组一半的形态学血管病变cv2改变、肾小管萎缩ct1和ct2以及间质纤维化ci2进行分级。在随访期间,患者接受相似剂量的泼尼松以及硫唑嘌呤和环孢素A。
通过间接免疫过氧化物酶染色技术(DAKOPATTS)在冰冻切片上分析MHC I抗原、MHC II抗原、CD3、CD25、CD54(ICAM-1)的表达。免疫反应评分从0到3。
肾功能以反映移植后第3至22个月平均每月水平的血清肌酐倒数(1/μmol/L)表示。在每位患者中,肾功能下降通过两种方式确定:1. 从移植后第3个月开始,以代表血清肌酐倒数随时间回归功能的曲线斜率;2. 与移植后第3个月达到的血清肌酐水平相比,在第6、9、18和22个月时血清肌酐倒数的回归率(百分比)。
存在慢性移植性肾小球病的肾小球(ChR-1组患者)MHC I抗原表达中等[1 - 2],ICAM-1(CD54)表达较弱,而DR抗原几乎缺失。在皮质肾小管中,MHC I抗原表达非常低。没有慢性移植性肾小球病的患者(ChR-2组)中相对保存完好的肾小球显示MHC I抗原高表达[2],ICAM-1中等表达,DR表达低(最高为1)。在所有分析的肾小球(共62个)中均未检测到CD25分子,除了在3例患有慢性移植性肾小球病的患者中观察到阳性细胞新月体形成。两组患者在第3至22个月期间血清肌酐倒数随时间的回归斜率相似,推测两组的平均移植肾存活时间均为44个月。然而,ChR-1组的8例患者中有4例,ChR-2组的8例患者中只有1例因移植肾功能丧失而恢复血液透析。此外,在活检标本中存在慢性移植性肾小球病的ChR-1组,在第3个月后的选定时间段内,作为血清肌酐倒数下降率的肾功能下降平均百分比更高。在第18个月结束时差异具有统计学意义,t = 4.10,p < 0.01。在此期间,ChR-1组有6例患者蛋白尿超过每天3克,ChR-2组有4例患者出现蛋白尿。我们的结果表明,慢性移植性肾小球病的早期出现会导致慢性排斥反应的肾移植功能丧失略高,尽管存在慢性移植性肾小球病的肾小球中没有免疫激活。(摘要截断)